EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

2022 FDA TIDES (Peptides and Oligonucleotides) Harvest

Othman Al Musaimi iD, Danah Al Shaer iD, Fernando Albericio iD, Beatriz G de la Torre iD

Pharmaceuticals · 22.02.2023 · 16 (3) · 336

DOI: 10.3390/ph16030336 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 22.02.2023. Verfasst von Othman Al Musaimi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation, University of KwaZulu-Natal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A total of 37 new drug entities were approved in 2022; although that year registered the lowest number of drug approvals since 2016, the TIDES class consolidated its presence with a total of five authorizations (four peptides and one oligonucleotide). Interestingly, 23 out of 37 drugs were first-in-class and thus received fast-track designation by the FDA in categories such as breakthrough therapy, priority review voucher, orphan drug, accelerated approval, and so on. Here, we analyze the TIDES approved in 2022 on the basis of their chemical structure, medical target, mode of action, administration route, and common adverse effects.

Schlagwörter

Stichwörter der Autor:innen

FDAdrugsgadopiclenollutetium (177Lu) vipivotide tetraxetanoligonucleotidespeptidesterlipressintirzepatidevutrisiran

Autor:innen und Institutionen

  • Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK.
  • Department of Medicinal Chemistry, Evotec (UK) Ltd., Abingdon OX14 4R, UK.
  • School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa.
  • CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain.
  • KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa.

ORCID-Profile: Othman Al Musaimi, Danah Al Shaer, Fernando Albericio, Beatriz G de la Torre

Förderung

  • National Research Foundation
  • University of KwaZulu-Natal

Zitieren

APA

Al Musaimi, O., Al Shaer, D., Albericio, F., & de la Torre, B. G. (2023). 2022 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals, 16(3), 336. https://doi.org/10.3390/ph16030336

Vancouver

Al Musaimi O, Al Shaer D, Albericio F, de la Torre BG. 2022 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals. 2023;16(3):336. doi:10.3390/ph16030336

BibTeX
@article{AlMusaimi2023,
  author = {Al Musaimi, Othman and Al Shaer, Danah and Albericio, Fernando and de la Torre, Beatriz G},
  title = {2022 FDA TIDES (Peptides and Oligonucleotides) Harvest},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {3},
  pages = {336},
  doi = {10.3390/ph16030336}
}
Kostenlos starten →